Literature DB >> 20631118

Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia.

Andrew F Shorr1, Nadia Haque, Charu Taneja, Marcus Zervos, Lois Lamerato, Smita Kothari, Sophia Zilber, Susan Donabedian, Mary Beth Perri, James Spalding, Gerry Oster.   

Abstract

While the increasing importance of methicillin-resistant Staphylococcus aureus (MRSA) as a pathogen in health care-associated S. aureus pneumonia has been documented widely, information on the clinical and economic consequences of such infections is limited. We retrospectively identified all patients admitted to a large U.S. urban teaching hospital between January 2005 and May 2008 with pneumonia and positive blood or respiratory cultures for S. aureus within 48 h of admission. Among these patients, those with suspected health care-associated pneumonia (HCAP) were identified using established criteria (e.g., recent hospitalization, admission from nursing home, or hemodialysis). Subjects were designated as having methicillin-resistant (MRSA) or methicillin-susceptible (MSSA) HCAP, based on initial S. aureus isolates. Initial therapy was designated "appropriate" versus "inappropriate" based on the expected susceptibility of the organism to the regimen received. We identified 142 patients with evidence of S. aureus HCAP. Their mean (standard deviation [SD]) age was 64.5 (17) years. Eighty-seven patients (61%) had initial cultures that were positive for MRSA. Most ( approximately 90%) patients received appropriate initial antibiotic therapy (86% for MRSA versus 91% for MSSA; P = 0.783). There were no significant differences between MRSA and MSSA HCAP patients in mortality (29% versus 20%, respectively), surgery for pneumonia (22% versus 20%), receipt of mechanical ventilation (60% versus 58%), or admission to the intensive care unit (79% versus 76%). Mean (SD) total charges per admission were universally high ($98,170 [$94,707] for MRSA versus $104,121 [$91,314]) for MSSA [P = 0.712]). Almost two-thirds of patients admitted to hospital with S. aureus HCAP have evidence of MRSA infection. S. aureus HCAP, irrespective of MRSA versus MSSA status, is associated with significant mortality and high health care costs, despite appropriate initial antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631118      PMCID: PMC2937709          DOI: 10.1128/JCM.02529-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.

Authors:  W S Lim; M M van der Eerden; R Laing; W G Boersma; N Karalus; G I Town; S A Lewis; J T Macfarlane
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Authors:  Levita K Hidayat; Donald I Hsu; Ryan Quist; Kimberly A Shriner; Annie Wong-Beringer
Journal:  Arch Intern Med       Date:  2006-10-23

3.  Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus.

Authors:  Dennis L Stevens; Yongsheng Ma; Daniel B Salmi; Eric McIndoo; Randi J Wallace; Amy E Bryant
Journal:  J Infect Dis       Date:  2006-12-18       Impact factor: 5.226

4.  Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia.

Authors:  Marin H Kollef; Andrew Shorr; Ying P Tabak; Vikas Gupta; Larry Z Liu; R S Johannes
Journal:  Chest       Date:  2005-12       Impact factor: 9.410

5.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Authors:  G Lina; Y Piémont; F Godail-Gamot; M Bes; M O Peter; V Gauduchon; F Vandenesch; J Etienne
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

6.  A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.

Authors:  Mandy Wootton; Alasdair P MacGowan; Timothy R Walsh; Robin A Howe
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

7.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Alex Soriano; Francesc Marco; José A Martínez; Elena Pisos; Manel Almela; Veselka P Dimova; Dolores Alamo; Mar Ortega; Josefina Lopez; Josep Mensa
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

Authors:  R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

9.  Health care-associated pneumonia and community-acquired pneumonia: a single-center experience.

Authors:  Scott T Micek; Katherine E Kollef; Richard M Reichley; Nareg Roubinian; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191

10.  Health care-associated native valve endocarditis: importance of non-nosocomial acquisition.

Authors:  Natividad Benito; José M Miró; Elisa de Lazzari; Christopher H Cabell; Ana del Río; Javier Altclas; Patrick Commerford; Francois Delahaye; Stefan Dragulescu; Helen Giamarellou; Gilbert Habib; Adeeba Kamarulzaman; A Sampath Kumar; Francisco M Nacinovich; Fredy Suter; Christophe Tribouilloy; Krishnan Venugopal; Asuncion Moreno; Vance G Fowler
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

View more
  16 in total

1.  Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus.

Authors:  Nadia Z Haque; Samia Arshad; Paula Peyrani; Kimbal D Ford; Mary B Perri; Gordon Jacobsen; Katherine Reyes; Ernesto G Scerpella; Julio A Ramirez; Marcus J Zervos
Journal:  J Clin Microbiol       Date:  2012-02-15       Impact factor: 5.948

2.  Rapid diagnostic test and use of antibiotic against methicillin-resistant Staphylococcus aureus in adult intensive care unit.

Authors:  A-F Dureau; G Duclos; F Antonini; D Boumaza; N Cassir; J Alingrin; C Vigne; E Hammad; L Zieleskiewicz; M Leone
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-07       Impact factor: 3.267

3.  Financial impact of health care-associated infections: When money talks.

Authors:  Louis Valiquette; Claire Nour Abou Chakra; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-03       Impact factor: 2.471

4.  Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: a comparison of the EUVAP and LATINVAP study cohorts.

Authors:  J Rello; D Molano; M Villabon; R Reina; R Rita-Quispe; I Previgliano; E Afonso; M I Restrepo
Journal:  Med Intensiva       Date:  2012-06-28       Impact factor: 2.491

5.  Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres.

Authors:  David B Huang; Ian Morrissey; Timothy Murphy; Stephen Hawser; Mark H Wilcox
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-08       Impact factor: 3.267

6.  Epidemiology of methicillin-resistant Staphylococcus aureus pneumonia in community hospitals.

Authors:  Sarah S Lewis; Vanessa J Walker; Mi Suk Lee; Luke Chen; Rebekah W Moehring; Christopher E Cox; Daniel J Sexton; Deverick J Anderson
Journal:  Infect Control Hosp Epidemiol       Date:  2014-10-24       Impact factor: 3.254

7.  Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.

Authors:  Pamela R Tessier; Rebecca A Keel; Mao Hagihara; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

8.  Endoscopic procedure as a diagnostic tool for intestinal parasitic pathological changes.

Authors:  Haytham M M Azab; Ahmed M S Bayoumy; Tarek K Zaalouk; Yousry Z El-Zeheiry; El-Sayed M Mohie El-Dein
Journal:  Parasitol Res       Date:  2021-11-10       Impact factor: 2.289

9.  Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus.

Authors:  Diana Cordero; Christopher R Fullenkamp; Rachel R Pelly; Katie M Reed; Lindy M Caffo; Ashley N Zahrt; Micaleah Newman; Sarah Komanapalli; Evan M Niemeier; Derron L Bishop; Heather A Bruns; Mark K Haynes; Larry A Sklar; Robert E Sammelson; Susan A McDowell
Journal:  Curr Pharm Biotechnol       Date:  2014       Impact factor: 2.837

10.  Nosocomial methicillin resistant Staphylococcus aureus pneumonia - epidemiology and trends based on data of a network of 586 German ICUs (2005-2009).

Authors:  Elisabeth Meyer; F Schwab; P Gastmeier
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.